<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00365924</url>
  </required_header>
  <id_info>
    <org_study_id>A9001294</org_study_id>
    <nct_id>NCT00365924</nct_id>
  </id_info>
  <brief_title>A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Forteo</brief_title>
  <official_title>A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Recombinant Human Parathyroid Hormone, PTH (Forteo)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This methodology trial will be conducted in patients with osteoporosis and will measure the
      changes in bone quality parameters, micro- and macroarchitecture, bone biomarkers and bone
      density following therapy with the approved drug, Forteo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in bone quality parameters (micro- and macroarchitecture) in osteoporotic postmenopausal women following 12 months of therapy with Forteo</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in BMD and bone biomarkers following 12 months of therapy with Forteo</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Forteo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Forteo</intervention_name>
    <description>Open label single arm study with Forteo as an intervention</description>
    <arm_group_label>Forteo</arm_group_label>
    <other_name>Recombinant Human PTH 1-34</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women with osteoporosis

        Exclusion Criteria:

          -  Any therapies or products affecting bone turnover within 12 months of Screening.

          -  Bisphosphonate treatment &gt;1 month in total duration at any time in the past.

          -  In addition, patients must be bisphosphonate-treatment-free for at least 12 months
             prior to Screening.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1055AAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1428AQK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Capital Federal - Buenos Aires</city>
        <zip>C1012AAP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9001294&amp;StudyName=A%20Pilot%20Methodology%20Study%20To%20Evaluate%20Changes%20In%20Bone%20Quality%20Parameters%20Following%20Therapy%20With%20Forteo</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2006</study_first_submitted>
  <study_first_submitted_qc>August 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2006</study_first_posted>
  <last_update_submitted>March 20, 2009</last_update_submitted>
  <last_update_submitted_qc>March 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>12 month therapy with postmenopausal women with osteoporosis to examine changes in bone quality parameters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

